Login to Your Account



INTERCEPT'S STOCK SOARS CLOSE TO 300%

FLINT mint: Intercept on fire with Phase IIb liver victory

By Randy Osborne
Staff Writer

Friday, January 10, 2014
Wall Street rejoiced over Intercept Pharmaceuticals Inc.’s stoppage for efficacy of the FLINT Phase IIb trial with obeticholic acid (OCA) for the treatment of non-alcoholic steatohepatitis (NASH) – “the coming tsunami of liver disease,” said CEO Mark Pruzanski.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription